NUWE
HEALTHCARENuwellis Inc
$1.09-0.02 (-1.80%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving NUWE Today?
No stock-specific AI insight has been generated for NUWE yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.96$43.26
$1.09
Fundamentals
Market Cap$3M
P/E Ratio—
EPS$-25.39
Dividend Yield—
Dividend / Share—
ROE-3.8%
Profit Margin-2.1%
Debt / Equity—
Trading
Volume48K
Avg Volume (10D)—
Shares Outstanding2.6M
NUWE News
20 articles- Nuwellis, Inc. To Announce First Quarter 2026 Financial Results on May 12, 2026Yahoo Finance·May 5, 2026
- Nuwellis Highlights Case Study Featuring Precision Ultrafiltration Therapy in Pediatric Cardiorenal Care at ISHLT 2026 Annual MeetingYahoo Finance·Apr 29, 2026
- Nuwellis Announces Receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for Innovative Dual Lumen Midline Catheter TechnologyYahoo Finance·Apr 28, 2026
- Nuwellis to Participate in the AATS 106th Annual Meeting and ERAS Cardiac Spring RetreatYahoo Finance·Apr 23, 2026
- Nuwellis Announces Aquadex Software UpdateYahoo Finance·Apr 21, 2026
- Nuwellis Welcomes Back Three Former Team Members to Accelerate Commercial and Clinical MomentumYahoo Finance·Apr 16, 2026
- Nuwellis Engages CORE IR for Public Relations, Shareholder Communications, and Social Media Management ServicesYahoo Finance·Apr 9, 2026
- Nuwellis Strengthens Commercial Infrastructure with New South Texas TerritoryYahoo Finance·Apr 7, 2026
- Nuwellis Pediatric Category Achieves Approximately 50% of Total U.S. Revenue in 2025, Marking Growth MilestoneYahoo Finance·Mar 31, 2026
- Nuwellis Completes Acquisition of RendiatechYahoo Finance·Mar 17, 2026
- Nuwellis, Inc. Q4 2025 Earnings Call SummaryMoby·Mar 10, 2026
- Nuwellis (NUWE) Q4 2025 Earnings Call TranscriptMotley Fool·Mar 10, 2026
- Nuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial ResultsYahoo Finance·Mar 10, 2026
- Nuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Strategy to Advance Pediatric and Cardiorenal StrategyYahoo Finance·Mar 5, 2026
- Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of DirectorsYahoo Finance·Feb 26, 2026
- Nuwellis, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026Yahoo Finance·Feb 24, 2026
- Nuwellis Appoints Carisa Schultz as Chief Financial OfficerYahoo Finance·Jan 30, 2026
- Nuwellis Announces $5 Million Private Placement and Warrant Inducement Transaction, Priced At-The-MarketYahoo Finance·Jan 29, 2026
- Nuwellis Enters into Definitive Agreement to Acquire Rendiatech, Advancing Its Cardiorenal Portfolio StrategyYahoo Finance·Jan 29, 2026
- BC-Most Active StocksYahoo Finance·Jan 27, 2026
All 20 articles loaded
Price Data
Open$1.16
Previous Close$1.11
Day High$1.16
Day Low$1.07
52 Week High$43.26
52 Week Low$0.96
52-Week Range
$0.96$43.26
$1.09
Fundamentals
Market Cap$3M
P/E Ratio—
EPS$-25.39
Dividend Yield—
Dividend / Share—
ROE-3.8%
Profit Margin-2.1%
Debt / Equity—
Trading
Volume48K
Avg Volume (10D)—
Shares Outstanding2.6M
About Nuwellis Inc
Nuwellis, Inc., a medical device company, focuses on the development, manufacture and marketing of medical devices used in ultrafiltration therapy. The company is headquartered in Eden Prairie, Minnesota.
HEALTHCAREMEDICAL DEVICES
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICMEDICAL DEVICES
CIK—
Composite FIGI—
Share Class FIGI—